Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1145520220080020157
Journal of Radiopharmaceuticals and Molecular Probes
2022 Volume.8 No. 2 p.157 ~ p.166
Recent Progress in Alpha-emitting Radiopharmaceutical Development for Clinical Application
Kang Choong-Mo

Choe Yearn-Seong
Abstract
Targeted alpha therapy began to be applied to the treatment of late-stage cancer patients because of its dramatic therapeutic efficacy in patients who have no responses with beta-emitting radiopharmaceuticals. However, its strong cytotoxicity may cause side effects due to undesirable uptake in non-target tissues. In order to use alpha-emitting radiopharmaceuticals for early-stage patients as well as late-stage cancer patients, therefore, modifications on their chemical structures are required. In this review, the recent progress in the development of alpha-emitting radiopharmaceuticals is discussed.
KEYWORD
Targeted alpha therapy, Alpha-emitting radiopharmaceuticals, Cancer, Pretargeted radioimmunotherapy, Radioimmunotherapy, Side effect
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)